


姓名:	張俊欽	填表日期: (YYYY/MM/DD)	2023/2/16	
單位:	內科部心臟內科	現職職稱:	主治醫師	
Email:	ccchang16@vghtpe.gov.tw	連絡電話:	89093	
學歷:	國立陽明大學臨床醫學研究所 國立陽明大學醫學士			
重要經歷:	2018/3-2019/8 荷蘭伊拉斯謨醫學中心 心臟血管介入專科 進修醫師 2015/4-2015/5 日本神戶大學附設醫院 心導管室 進修醫師 2012/8-2015/8 臺北榮民總醫院 內科部心臟科 總醫師 2009/9-2012/7 臺北榮民總醫院 內科部 住院醫師			
研究方向: (關鍵詞)	心導管與介入性治療研究、週邊血管介入性治療研究、心臟瓣膜介入性治療研究。			
五年內 代表著作:	<ol style="list-style-type: none"> 1. Agreement Between Invasive Wire-Based and Angiography-Based Vessel Fractional Flow Reserve Assessment on Intermediate Coronary Stenoses. Chun-Chin Chang, Yin-Hao Lee, Ming-Ju Chuang, Chien-Hung Hsueh, Ya-Wen Lu, Yi-Lin Tsai, Ruey-Hsing Chou, Cheng-Hsueh Wu, Tse-Min Lu, Po-Hsun Huang, Shing-Jong Lin, Robert-Jan van Geuns. Front Cardiovasc Med. 2021 Jun 30;8:707454. doi:10.3389/fcvm.2021.707454. eCollection 2021. 2. Uncertainties and challenges in surgical and transcatheter tricuspid valve therapy: a state-of-the-art expert review. Chang CC, Veen KM, Hahn RT, Bogers AJJC, Latib A, Oei FBS, Abdelghani M, Modolo R, Ho SY, Abdel-Wahab M, Fattouch K, Bosmans J, Caliskan K, Taramasso M, Serruys PW, Bax JJ, van Mieghem NMDA, Takkenberg JJM, Lurz P, Modine T, Soliman O. Eur Heart J. 2019 Sep 11. pii: ehz614. doi: 10.1093/eurheartj/ehz614. 3. Optical Coherence Tomography Assessment for Percutaneous Coronary Intervention of the Left Main Artery: The IDEAL-LM Trial. Chun Chin Chang, Yoshinobu Onuma, Maciej Lesiak, Evgeny Merkulov, Richard Anderson, Evgeny Kretov, Paul Barragan, Keith G Oldroyd, Robert-Jan van Geuns. JACC Cardiovasc Interv. 2020 Feb 10;13(3):401-402. doi: 10.1016/j.jcin.2019.09.012. Epub 2019 Sep 26. 4. Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial). Chang CC, Spitzer E, Chichareon P, Takahashi K, Modolo R, Kogame N, Tomaniak M, Komiyama H, Yap SC, Hoole SP, Gori T, Zaman A, Frey B, Ferreira RC, Bertrand OF, Koh TH, Sousa A, Moschovitis A, van Geuns RJ, Steg PG, Hamm C, Jüni P, Vranckx P, Valgimigli M, Windecker S, Serruys PW, Soliman O, Onuma Y. Am J Cardiol. 2019 Dec 15;124(12):1833-1840. 			

5. Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study. **Chang CC**, Chichareon P, Modolo R, Takahashi K, Kogame N, Tomaniak M, Gao C, Roybaards KJ, Cequier A, Oldroyd K, Steg PG, Hamm C, Jüni P, Valgimigli M, Windecker S, Onuma Y, Stables RH, Jan van Geuns R, Serruys PW. Eur Heart J Cardiovasc Pharmacother. 2019 Dec 9. pii: pvz051. doi: 10.1093/ehjcvp/pvz051.
6. Defining Device Success for Percutaneous Coronary Intervention Trials: A Position Statement from the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology. **Chang CC**, Kogame N, Onuma Y, Byrne RA, Capodanno D, Windecker S, Morel MA, Cutlip DE, Krucoff MW, Stone GW, Lansky AJ, Mehran R, Spitzer E, Fraser AG, Baumbach A, Serruys PW. EuroIntervention. 2019 Sep 3. pii: EIJ-D-19-00552.
7. BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: three-year clinical outcomes of the PIONEER trial. **Chang CC**, Kogame N, Asano T, von Birgelen C, Sabaté M, Onuma Y, Serruys PW. EuroIntervention. 2019 Jul 30. pii: EIJ-D-19-00566.
8. Absorb Bioresorbable Scaffold Versus Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis: Rationale and Design of the COMPARE ABSORB Trial. **Chang CC**, Onuma Y, Achenbach S, Barbato E, Chevalier B, Cook S, Dudek D, Escaned J, Gori T, Kočka V, Tarantini G, West NEJ, Morice MC, Tijssen JGP, van Geuns RJ, Smits PC; COMPARE ABSORB trial investigators. Cardiovasc Revasc Med. 2019 Jul;20(7):577-582.

研究室成員: 張俊欽、李佳蓁